Congenital Conditions
Late-breaking data from the Phase 3 HOPE-3 trial of deramiocel in Duchenne muscular dystrophy, presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, suggest potential benefits across cardiac and functional outcomes. The investigational first-in-class therapy is currently under review by the FDA for the treatment of DMD cardiomyopathy, with a Prescription Drug User Fee Act target action date of 22 August, 2026.
Adult congenital heart disease is no longer a niche condition confined to childhood, but a lifelong and increasingly complex cardiovascular diagnosis. The new ACC/AHA guideline reframes care around continuity with specialised services, proactive mental health assessment, and encouragement of safe physical activity, signalling a shift from lesion-focused surveillance to holistic, life-course management that better reflects the realities facing today’s adult patients.
The 2025 American Heart Association (AHA) Scientific Sessions (7–10 November; New Orleans, LA, USA) offered a comprehensive overview of the evolving landscape of cardiovascular medicine. This year’s research showcased pivotal trials spanning indications, including hypercholesterolemia, hypertrophic cardiomyopathy, amyloidosis, severe hypertriglyceridaemia, hypertension, ...
Gene therapies are redefining the landscape of cardiovascular treatment, offering targeted solutions for conditions like heart failure, hypertrophic cardiomyopathy, and amyloidosis. Using advanced techniques such as viral vector delivery, RNA modulation, and CRISPR-based editing, these therapies aim to address root genetic causes. While challenges in delivery and safety remain, early clinical data signal a promising shift toward more durable and precise cardiac interventions.
The touchCARDIO journal Heart International has once again seen an increase in its Journal Impact Factor (JIF), rising from 1.9 in 2024 to 2.3 in 2025.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
May 2025 saw several significant developments in the field of cardiology, including new regulatory approvals, long-term clinical trial data and important findings from late-breaking studies. This roundup highlights the latest updates across structural, interventional and heart failure therapies, with implications for ...
The ACT-EARLY clinical trial has dosed its first participant in an effort to prevent variant transthyretin amyloidosis (ATTRv) in genetically at-risk individuals. By evaluating the selective TTR stabilizer, acoramidis, in asymptomatic carriers, the study aims to delay or halt disease onset. With approximately 600 participants, ACT-EARLY marks a pivotal step toward shifting ATTRv care from reactive treatment to proactive prevention.
Novel oral therapy shows a 3.3% increase in left ventricular ejection fraction, marking a potential breakthrough in treating Duchenne muscular dystrophy cardiomyopathy In a positive development for the Duchenne muscular dystrophy (DMD) community, Cumberland Pharmaceuticals (Nashville, TN, USA) has announced positive ...
touchCARDIO is delighted to announce that Heart International has received an impressive new Impact Factor of 1.9 in the 2024 Journal Citation Reports (JCR). This achievement marks a notable increase from last year’s Impact Factor of 0.2 and highlights the journal’s growing influence in the cardiology field.
Our society partner, NORD (The National Organization for Rare Disorder) has planned several initiatives to support this year’s Rare Disease Day on 28 February. These activities are aimed at raising awareness about rare diseases and the challenges faced by people ...
Rare diseases can present numerous challenges for those living with these conditions and the healthcare professionals caring for them. In this interview we discuss some of these with Lisa Sarfaty, VP of Communication and Engagement for NORD (The National Organization ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
